NVDA Stock: Where Compounding Could Take The Price

While the world sees a GPU company, management is building a major business in a market it has never addressed before. The company now has visibility to nearly $20 billion in total CPU revenue this year. This shift reframes the growth story from components to full systems.

This expansion is why the upside case hinges on revenue. The company is no longer just selling accelerators; it is assembling the AI factories that define modern data centers. This systems-level strategy dramatically expands the addressable market.

That’s the story for NVIDIA (NVDA). The question is whether it’s strong enough to deliver real upside from here, or whether today’s price has already absorbed most of the optimism. Mostly yes. A conservative 3-year scenario points to roughly 56% of upside in NVDA, and the operational story carries it. The earnings line is moving in the right direction, but a softer multiple is set to chew a meaningful chunk of that out before it reaches the stock. Here is the operational picture the math sits on top of:

*LTM: Last Twelve Months

How Compounding Builds The Upside

Revenue compounds at 30% annually, taking the top line from $253.5B to $556.9B over three years. That is a further step down from the LTM 71% pace, in line with the deceleration the business is already showing.

Margins ease from 63% to 60% as today’s LTM reverts partway toward the 3-year average of 52%. Together that takes earnings from $159.6B to roughly $331.5B, a 108% jump.

Here is where the stock and the earnings line diverge. NVDA’s P/E already sits at 28.9x, below its 3-year average of 54.1x. The scenario trims it further to 21.7x, because a slower forward growth rate no longer supports even today’s multiple. That single move chews roughly 25% out of what the earnings growth would otherwise have delivered. Apply the lower multiple to the higher earnings and the stock lands near $296.01, a market cap of $7.2T against $4.6T today. That is roughly 56% above where the stock trades now. The earnings line is doing the work; the multiple is taking a meaningful cut of it before it reaches the share price.

Has revenue compounding been the lever driving NVDA’s recent move? See the lever breakdown.

What Could Accelerate The Top Line

The next leg of growth could come from a category not yet in the run-rate. The new VeraCPU opens a brand new $200 billion TAM for NVIDIA. Capturing even a fraction of this market adds a material new layer to the revenue base.

What Could Slow It Down

The primary risk surfaced on the call is the pace of its own product cycle. When asked to compare the upcoming VeraRubin ramp to Blackwell’s, management conceded it is hard to say at this point. It is still a little early to say if the next generation can match the current velocity.

Is The Compounding Real?

For the case to play out, the deceleration has to stabilize around 30% rather than continuing lower. The multiple is the other moving piece: the case trims it from 28.9x to 21.7x to reflect a slower forward growth rate, not any re-rating. If growth holds up better than projected, that compression reverses and the upside is larger.

The new $200 billion TAM for Vera is a tangible catalyst, while uncertainty over the VeraRubin ramp feels more like a question of timing than trajectory.

Should You Invest In NVIDIA?

For a different read on NVDA, see our recent piece What Could Push NVDA Stock Higher From Here?

A careful 3-year case on a single name is still a concentrated bet, as historical volatility across past market crises shows. Investors who build analyses like this on individual positions often want the same framework running across a diversified book, partly for discipline, partly because even the cleanest single-stock thesis can break for reasons the math does not capture.

If it is exposure to technology as a whole you want rather than this one name, a technology ETF like VGT covers that single sector. Going broader than any one sector, to a quality-first mix across the whole market, is where the portfolio below comes in.

The Trefis High Quality (HQ) Portfolio combines analytical rigor with a forward-looking view across 30 stocks, with a consistent selection framework and a sizing and re-balancing discipline designed to deliver upside without the single-name risk you just read through here.

By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.